Susceptibility of Human Head and Neck Cancer Cells to Combined Inhibition of Glutathione and Thioredoxin Metabolism

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Sobhakumari, Arya ^a,b   Love Homan, Laurie ^a   Fletcher, Elise V M ^a,b   Martin, Sean M ^a   Parsons, Arlene D ^a   Spitz, Douglas R ^a,b,c   Knudson, C Michael ^a,c   Simons, Andrean L ^a,b,c  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AURANOFIN; BUTHIONINE SULFOXIMINE; CASPASE 3; CASPASE 7; CATALASE; ERLOTINIB; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; PEROXIREDOXIN; PROTEIN BAK; PROTEIN BAX; SELENIUM; THIOREDOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL KILLING; CELL STRAIN CAL 27; CELL STRAIN FADU; CELL STRAIN SCC 25; CELL SURVIVAL; CELL VIABILITY; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SENSITIVITY; ENZYME INHIBITION; FEMALE; GLUTATHIONE METABOLISM; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METABOLIC INHIBITION; MOUSE; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PROTEIN METABOLISM; TREATMENT DURATION; TUMOR NECROSIS; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AURANOFIN; BUTHIONINE SULFOXIMINE; CARCINOMA, SQUAMOUS CELL; CATALASE; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SYNERGISM; FEMALE; GENE KNOCKDOWN TECHNIQUES; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; HEAD AND NECK NEOPLASMS; HUMANS; MICE; MICE, NUDE; NECROSIS; OXIDATION-REDUCTION; OXIDATIVE STRESS; PEROXIREDOXINS; QUINAZOLINES; RNA, SMALL INTERFERING; THIOREDOXIN-DISULFIDE REDUCTASE; THIOREDOXINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84868286860     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048175     Document Type: Article

References (53)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2008) Cancer statistics. CA Cancer J Clin 58 (2) (): 71-96.
2. Mao L, Hong WK, Papadimitrakopoulou VA, (2004) Focus on head and neck cancer. Cancer Cell 5 (4) (): 311-316.
3. Shah JP, Lydiatt W, (1995) Treatment of cancer of the head and neck. CA Cancer J Clin 45 (6) (): 352-368.
4. Eriksson SE, Prast-Nielsen S, Flaberg E, Szekely L, Arnér ES, (2009) High levels of thioredoxin reductase 1 modulate drug-specific cytotoxic efficacy. Free Radic Biol Med 47 (11) (): 1661-1671.
5. Corti A, Franzini M, Paolicchi A, Pompella A, (2010) Gamma-glutamyltransferase of cancer cells at the crossroads of tumor progression, drug resistance and drug targeting. Anticancer Res 30 (4) (): 1169-1181.
6. Rabik CA, Dolan ME, (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. Canc Treat Rev 33 (1) (): 9-23.
7. Spitz DR, Phillips JW, Adams DT, Sherman CM, Deen DF, et al. (1993) Cellular resistance to oxidative stress is accompanied by resistance to cisplatin: the significance of increased catalase activity and total glutathione in hydrogen peroxide-resistant fibroblasts. J Cell Physio 156 (1) (): 72-79.
8. Mitchell JB, Russo A, (1987) The role of glutathione in radiation and drug induced cytotoxicity. Br J Cancer Suppl 8: pp. 96-104.
9. Spitz DR, Kinter MT, Roberts RJ, (1995) Contribution of increased glutathione content to mechanisms of oxidative stress resistance in hydrogen peroxide resistant hamster fibroblasts. J Cell Physiol 165 (3) (): 600-609.
10. Hayes JD, McLellan LI, (1999) Glutathione and glutathione-dependent enzymes represent a co-ordinately regulated defence against oxidative stress. Free Radic Res 31: 273-300.
11. Song JJ, Lee YJ, (2003) Differential role of glutaredoxin and thioredoxin in metabolic oxidative stress-induced activation of apoptosis signal-regulating kinase 1. Biochem J 373 (Pt 3) (): 845-853.
12. Schafer FQ, Buettner GR, (2001) Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med 30: 1191-1212.
13. Mustacich D, Powis G, (2007) Thioredoxin reductase. Biochem J 346: 1-8.
14. Siegsmund MJ, Marx C, Seemann O, Schummer B, Steidler A, et al. (1999) Cisplatin-resistant bladder carcinoma cells: enhanced expression of metallothioneins. Urol Res 27 (3) (): 157-163.
15. Lai SL, Hwang J, Perng RP, Whang-Peng J, (1995) Modulation of cisplatin resistance in acquired-resistant non-small cell lung cancer cells. Oncol Res 7 (1) (): 31-38.
16. Simons AL, Parsons AD, Foster KA, Orcutt KP, Fath MA, et al. (2009) Inhibition of glutathione and thioredoxin metabolism enhances sensitivity to perifosine in head and neck cancer cells. J Oncol 2009: 519563.
17. Marty L, Siala W, Schwarzländer M, Fricker MD, Wirtz M, et al. (2009) The NADPH-dependent thioredoxin system constitutes a functional backup for cytosolic glutathione reductase in Arabidopsis. Proc Natl Acad Sci U S A 106 (22) (): 9109-9114.
18. Tan SX, Greetham D, Raeth S, Grant CM, Dawes IW, et al. (2010) The thioredoxin-thioredoxin reductase system can function in vivo as an alternative system to reduce oxidized glutathione in Saccharomyces cerevisiae. J Biol Chem 285 (9) (): 6118-6126.
19. Reichheld JP, Khafif M, Riondet C, Droux M, Bonnard G, et al. (2007) Inactivation of thioredoxin reductases reveals a complex interplay between thioredoxin and glutathione pathways in Arabidopsis development. Plant Cell 19 (6) (): 1851-1865.
20. Mandal PK, Schneider M, Kölle P, Kuhlencordt P, Förster H, et al. (2010) Loss of thioredoxin reductase 1 renders tumors highly susceptible to pharmacologic glutathione deprivation. Cancer Res 70 (22) (): 9505-9514.
21. Weichselbaum RR, Dahlberg W, Beckett M, Karrison T, Miller D, et al. (1986) Radiation-resistant and repair-proficient human tumor cells may be associated with radiotherapy failure in head- and neck-cancer patients. Proc Natl Acad Sci U S A 83 (8) (): 2684-2688.
22. Spitz D, Malcolm R, Robert R, (1990) Cytotoxicity and metabolism of 4-hydroxy-2-nonenol and 2-nonenol in H2O2-resistant cell lines. Do aldehydic by-products of lipid peroxidation contribute to oxidative stress? Biochem J 267: 453-459.
23. Watson WH, Pohl J, Montfort WR, Stuchlik O, Reed MS, et al. (2003) Redox potential of human thioredoxin 1 and identification of a second dithiol/disulfide motif. J Biol Chem 278: 33408-33415.
24. Scarbrough PM, Mapuskar KA, Mattson DM, Gius D, Watson WH, et al. (2012) Simultaneous inhibition of glutathione and thioredoxin-dependent metabolism is necessary to potentiate 17AAG-induced cancer cell killing via oxidative stress. Free Radic Biol Med 52 (2) (): 436-443.
25. Fath MA, Ahmad IM, Smith CJ, Spence J, Spitz DR, (2011) Enhancement of carboplatin-mediated lung cancer cell killing by simultaneous disruption of glutathione and thioredoxin metabolism. Clin Cancer Res 17 (19) (): 6206-6217.
26. Mavis RD, Stellwagen E, (1968) Purification and subunit structure of glutathione reductase from bakers' yeast. J Biol Chem 243 (4) (): 809-814.
27. Lawrence RA, Burk RF, (1976) Glutathione peroxidase activity in selenium-deficient rat liver. Biochem Biophys Res Commun 71: 952-958.
28. Kim JA, Park S, Kim K, Rhee SG, Kang SW, (2005) Activity assay of mammalian 2-cys peroxiredoxins using yeast thioredoxin reductase system. Anal Biochem 338 (2) (): 216-223.
29. Aebi H, (1984) Catalase in vitro. Methods Enzymol 105: 121-126.
30. Lum JJ, Bauer DE, Kong M, Harris MH, Li C, et al. (2005) Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 120 (2) (): 237-248.
31. Kandasamy K, Srinivasula SM, Alnemri ES, Thompson CB, Korsmeyer SJ, et al. (2003) Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release. Cancer Res 63 (7) (): 1712-1721.
32. Cox AG, Brown KK, Arner ES, Hampton MB, (2008) The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax/Bak-dependent process that involves peroxiredoxin 3 oxidation. Biochem Pharmacol 76 (9) (): 1097-1109.
33. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, et al. (2002) Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62 (24) (): 7350-7356.
34. Bailey HH, (1998) L-S,R-buthionine sulfoximine: historical development and clinical issues. Chem Biol Interact 111: 39-54.
35. McKeage MJ, Maharaj L, Berners-Price SJ, (2002) Mechanisms of cytotoxicity and antitumor activity of gold(I) phosphine complexes: The possible role of mitochondria. Coord Chem Rev 232: 127-135.
36. Rigobello MP, Folda A, Baldoin MC, Scutari G, Bindoli A, (2005) Effect of Auranofin on the mitochondrial generation of hydrogen peroxide. Role of thioredoxin reductase. Free Rad Res 39: 7687-7695.
37. Rackham O, Shearwood AM, Thyer R, McNamara E, Davies SM, et al. (2011) Substrate and inhibitor specificities differ between human cytosolic and mitochondrial thioredoxin reductases: Implications for development of specific inhibitors. Free Radic Biol Med 50 (6) (): 689-699.
38. Bailey HH, Ripple G, Tutsch KD, Arzoomanian RZ, Alberti D, et al. (1997) Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan. J Natl Cancer Inst 89 (23) (): 1789-1796.
39. Yao K, Godwin AK, Ozols RF, Hamilton TC, O'Dwyer PJ, (1993) Variable baseline gamma-glutamylcysteine synthetase messenger RNA expression in peripheral mononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment. Cancer Res 53 (16) (): 3662-3666.
40. O'Dwyer PJ, Hamilton TC, Young RC, LaCreta FP, Carp N, et al. (1992) Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results. J Natl Cancer Ins 84 (4) (): 264-267.
41. Bailey HH, Mulcahy RT, Tutsch KD, Arzoomanian RZ, Alberti D, et al. (1994) Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. J Clin Oncol 12 (1) (): 194-205.
42. Gallo JM, Brennan J, Hamilton TC, Halbherr T, Laub PB, et al. (1995) Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO. Cancer Res 55 (20) (): 4507-4511.
43. Shaw CF III, (1999) Gold-based therapeutics agents. Chem Rev 99: 2589-2600.
44. Blocka K, (1983) Auranofin versus injectable gold. Comparison of pharmacokinetic properties. Am J Med 75 (6A) (): 114-122.
45. Schnier C, Benn HP, (1990) Whole body elimination routes of gold in humans after a single-dose application of the antirheumatic auranofin. Biol Trace Elem Res 26-27: 471-477.
46. Benn HP, Schnier C, Seiler KU, Bauer E, Löffler H, (1990) Pharmacokinetics of auranofin a single dose study in man. J Rheumatol 17 (4) (): 466-468.
47. Brown KK, Cox AG, Hampton MB, (2010) Mitochondrial respiratory chain involvement in peroxiredoxin 3 oxidation by phenethyl isothiocyanate and auranofin. FEBS Lett 584 (6) (): 1257-1262.
48. Bozonet SM, Findlay VJ, Day AM, Cameron J, Veal EA, et al. (2005) Oxidation of a eukaryotic 2-Cys peroxiredoxin is a molecular switch controlling the transcriptional response to increasing levels of hydrogen peroxide. J Biol Chem 280 (24) (): 23319-23327.
49. Armstrong JS, Steinauer KK, Hornung B, Irish JM, Lecane P, et al. (2002) Role of glutathione depletion and reactive oxygen species generation in apoptotic signaling in a human B lymphoma cell line. Cell Death Differ 9 (3) (): 252-263.
50. Troyano A, Fernández C, Sancho P, de Blas E, Aller P, (2001) Effect of glutathione depletion on antitumor drug toxicity (apoptosis and necrosis) in U-937 human promonocytic cells. The role of intracellular oxidation. J Biol Chem 276 (50) (): 47107-47115.
51. Grandis JR, Tweardy DJ, (1993) Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 53 (15) (): 3579-3584.
52. Zimmermann M, Zouhair A, Azria D, Ozsahin M, (2006) The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications. Radiat Oncol 1: 11.
53. Weber CN, Cerniglia GJ, Maity A, Gupta AK, (2007) Bortezomib sensitizes human head and neck carcinoma cells SQ20B to radiation. Cancer Biol Ther 6 (2) (): 156-159.